Results 231 to 240 of about 910,276 (348)

Neuid: A Novel Neuron‐Enriched LncRNA that Connects Epigenetic Gene Silencing to Alzheimer's Disease

open access: yesAdvanced Science, EarlyView.
ABSTRACT The increasing evidence that non‐coding RNAs can become deregulated during pathogenesis is dramatically expanding the space for drug discovery beyond the protein‐coding genome. Long noncoding RNAs (lncRNAs) are emerging as key regulators of cellular function, yet most remain uncharacterized.
Ranjit Pradhan   +17 more
wiley   +1 more source

Systematic Benchmarking of a Noise‐Tolerant Conductive Hydrogel Electrode for Epidermal Bioelectronics

open access: yesAdvanced Science, EarlyView.
General schematic of the approach. Abstract Conventional Silver/Silver Chloride (Ag/AgCl) electrodes remain the clinical standard for electrophysiological monitoring but are hindered by poor skin conformity, mechanical rigidity, and signal degradation, particularly under motion or sweat.
Nazmi Alsaafeen   +11 more
wiley   +1 more source

Cuproptosis and Disulfidptosis Converge to Empower PD‐L1 Checkpoint Therapy via Cadict‐Induced PD‐L1 Translation

open access: yesAdvanced Science, EarlyView.
This study introduces Cadict, an EGFR‐targeted nanodrug that co‐delivers cuproptosis and disulfidptosis inducers to overcome immune resistance. Cadict synergistically enhances tumor cytotoxicity and sensitizes cancers to ICIs by upregulating PD‐L1 via an Eif5b‐dependent translation mechanism, fostering a potent antitumor immune response and ...
Shaoqing Huang   +12 more
wiley   +1 more source

Targeting Lactate and Lactylation in Cancer Metabolism and Immunotherapy

open access: yesAdvanced Science, EarlyView.
Lactate, once deemed a metabolic waste, emerges as a central regulator of cancer progression. This review elucidates how lactate and its epigenetic derivative, protein lactylation, orchestrate tumor metabolism, immune suppression, and therapeutic resistance.
Jiajing Gong   +5 more
wiley   +1 more source

pH/ROS‐Responsive Injectable Hydrogel Co‐Loaded with B7‐H3 Blocker and NETs Suppressor Boosts OSCC Synergistic Immunotherapy

open access: yesAdvanced Science, EarlyView.
A pH/ROS‐dual‐responsive injectable hydrogel, formed by dynamic boronic ester and Schiff base crosslinking, co‐delivers enoblituzumab (B7‐H3 blocker) and Cl‐amidine (NETs suppressor). Via localized intratumoral delivery, it synergistically reprograms the immunosuppressive tumor microenvironment, overcomes T cell infiltration barriers, restores ...
Huan Li   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy